[177Lu]Lu-NNS309

[177Lu]Lu-NNS309 is a radiopharmaceutical compound under development for the treatment of advanced solid tumors. It consists of a peptide (NNS309) that binds with high affinity to fibroblast activation protein (FAP), which is overexpressed in the tumor microenvironment of many cancers. The molecule includes a DOTA chelator for radiolabeling with lutetium-177 (^177Lu), enabling targeted delivery of ionizing radiation to FAP-expressing cells. This approach aims to selectively irradiate and destroy cancer-associated fibroblasts and adjacent tumor cells while sparing normal tissue. The drug is being developed as part of a theranostic pair alongside [68Ga]Ga-NNS309 for PET imaging, allowing patient selection and dosimetry prior to therapy. Primary indications under investigation include pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- breast cancer, triple negative breast cancer (TNBC), and colorectal cancer[1][2][4][6].

Brand names

lutetium lu 177-nns309

Other names

[177Lu] Lu NNS309¹⁷⁷Lu-Lu-NNS309